3rd Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Communication with Healthcare Information Technology Standards Panel Secretariat regarding HITSP Quality Interoperability Specification; Communication to Centers for Medicare and Medicaid Services in support of Joint Commission application for continued deeming authority for hospitals; Communications with CMS on the Hospital Outpatient Prospective Payment System; Communication with CMS on the Physician Fee Schedule; Meeting with CMS on compendia issues.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Health Issues HCR

FDA Appropriations FY10. Communication to White House Office on Health Care Reform. Letter and support for HR 2891, Access to Frontline Health Care Act of 2009, all provisions dealing with loan forgiveness for Title VII health professions. Testimony to House Energy and Commerce Committee on HR 3200, support second year specialized residency programs and medication therapy management grant program. Letters to Senate Finance Committee on residency funding.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 2891 (111th), H.R. 3200 (111th)

Pharmacy PHA

Meeting with FDA relating to removal of unapproved products, opportunities for future collaboration; Risk Evaluation and Mitigation Strategies. Meeting with FDA regarding design and use of NDC number.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.